Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

Dividend yields can be like ladders: The higher you go, the scarier it gets. Many investors are more leery of ultra-high ...

Canoo said on Friday night that it has filed for Chapter 7 bankruptcy and “will cease operations effective immediately,” ...